Kynurenic acid in blood and bone marrow plasma of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients

Leukemia Research

Volumn 34, Issue 1, 2010, Pages 38-45

  Zdzisińska, Barbara ^a   Wejksza, Katarzyna ^a   Walter Croneck, Adam ^b   Turski, Waldemar A ^b   Kandefer Szerszeń, Martyna ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Bone marrow stromal cells; Immune system; Kynurenic acid; Multiple myeloma

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; KYNURENIC ACID;

ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; CELL CULTURE; CELL LINE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; STROMA CELL; UREA BLOOD LEVEL; URINARY EXCRETION;

ADULT; AGED; BONE MARROW; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KYNURENIC ACID; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARAPROTEINEMIAS;

EID: 73249138907     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.06.015     Document Type: Article

References (47)

1. Stone T.W., and Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat Rev 1 (2002) 609-620
2. Swartz K.J., During M.J., Freese A., and Beal M.F. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J Neurosci 10 (1990) 2965-2973
3. Hilmas C., Pereira E.F.R., Alkondon M., Rassoulpour A., Schwarcz R., and Albuquerque E.X. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor expression: physiopathological implications. J Neurosci 21 (2001) 7463-7473
4. Luccini E., Musante V., Neri E., Raiteri M., and Pittaluga A. N-Methyl-d-aspartate autoreceptors respond to low and high agonist concentrations by facilitating, respectively, exocytosis and carrier-mediated release of glutamate in rat hippocampus. J Neurosci Res 85 16 (2007) 3657-3665
5. Prescott C., Weeks A.M., Staley K.J., and Partin K.M. Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett 402 (2006) 108-112
6. Heyes M.P., Saito K., Crowley J.S., Davis L.E., Demitrack M.A., Der M., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115 (1992) 1249-1273
7. Milart P., Urbańska E.M., Turski W.A., Paszkowski T., and Sikorski R. Intrapartum levels of endogenous glutamate antagonist-kynurenic acid in amniotic fluid, umbilical and maternal blood. Neurosci Res Commmun 24 (1999) 173-178
8. Swartz K.J., Matson W.R., MacGarvey U., Ryan E.A., and Beal M.F. Measurements of kynurenic acid in mammalian brain extracts and cerebrospinal fluid by high-performance liquid chromatography with fluorometric and coulometric electrode array detection. Anal Biochem 185 (1990) 363-376
9. Rejdak R., Zarnowski T., Turski W.A., Kocki T., Zagórski Z., Zrenner E., et al. Alterations of kynurenic acid content in retina in response to retinal ganglion cell damage. Vision Res 43 (2003) 497-503
10. Parada-Turska J., Rzeski W., Zgrajka W., Majdan M., Kandefer-Szerszeń M., and Turski W. Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro. Rheumatol Int 26 (2006) 422-426
11. Kuc D., Rahnama M., Tomaszewski T., Rzeski W., Wejksza K., Urbanik-Sypniewska T., et al. Kynurenic acid in human saliva-does it influence oral microflora?. Pharmacol Rep 58 (2006) 393-398
12. Kuc D., Zgrajka W., Parada-Turska J., Urbanik-Sypniewska T., and Turski W.A. Micromolar concentration of kynurenic acid in rat small intestine. Amino Acids 35 (2008) 503-505
13. Wang J., Simonavicius N., Wu X., Swaminath G., Reagan J., Tian H., et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 281 (2006) 22021-22028
14. Beal M.F., Matson W.R., Swartz K.J., Gamache P.H., and Bird E.D. Kynurenine pathway measurement in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 55 (1990) 1327-1339
15. Ilzecka J., Kocki T., Stelmasiak Z., and Turski W.A. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand 107 (2003) 412-418
16. Hartai Z., Klivenyi P., Janaky T., Penke B., Dux L., and Vecsei L. Kynurenine metabolism in multiple sclerosis. Acta Neurol Scand 112 (2005) 93-96
17. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., and Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 50 (2001) 521-530
18. Heyes M.P., Brew B.J., Saito K., Quearry B.J., Price R.W., Lee K., et al. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and β2-microglobulin in cerebrospinal fluid and serum of HIV-infected patients. J Neuroimmunol 40 (1992) 71-80
19. Hoshi M., Ito H., Fujigaki H., Takemura M., Takahashi T., Tomita E., et al. Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity. Leuk Res 33 (2009) 39-45
20. Karanikas V., Zamanakou M., Kerenidi T., Dahabreh J., Hevas A., Nakou M., et al. Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer. Cancer Biol Ther 6 (2007) 1258-1263
21. Schroecksnadel K., Winkler C., Fuith L.C., and Fuchs D. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett 223 (2005) 323-329
22. Huang A., Fuchs D., Winder B., Glover C., Henderson D.C., and Allen-Mersh T.G. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 86 (2002) 1691-1696
23. Brandacher G., Parathoner A., Ladurner R., Scheeberger S., Obrist P., Winkler C., et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect of tumor-infiltrating T cells. Clin Cancer Res 15 (2006) 1144-1151
24. Munn D.H., and Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117 (2007) 1147-1154
25. Saito K., Crowley J.S., Markey S., and Heyes M.P. A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J Biol Chem 268 (1993) 15496-15503
26. Schroecksnadel K., Fiegl M., Prassl K., Denz H.A., and Fuchs D. Diminished quality of life in patients with cancer correlates with tryptophan degradation. J Cancer Res Clin Oncol 133 (2007) 477-485
27. Xie J., Wang Y., Freeman M.E., Barlogie B., and Yi Q. Beta2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood 15 (2003) 4005-4012
28. Perez-Andres M., Almeida J., Martin-Ayuso M., Moro M.J., Garcia-Marcos M.A., Moreno I., et al. Red Espanola de Mieloma Multiple. Interactions between clonal plasma cells and the immune system in plasma cell dyscrasias. J Biol Regul Homeost Agents 18 (2004) 161-165
29. Ostad M., Andersson M., Gruber A., and Sundblad A. Expansion of immunoglobulin autoreactive T-helper cells in multiple myeloma. Blood 111 (2008) 2725-2732
30. Durie B.G., and Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36 (1975) 842-845
31. Greipp P.R., San Miguel J., Durie B.G.M., Crowley J.J., Barlogie B., Blade J., et al. International staining system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420
32. Hartai Z., Juhasz A., Rimanoczy A., Janaky T., Donko T., Dux L., et al. Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochemistry Int 50 (2007) 308-313
33. Kepplinger B., Baran H., Kainz A., Ferraz-Leite H., Newcombe J., and Kalina P. Age-related increase of kynurenic acid in human cerebrospinal fluid-IgG and β2-microglobulin changes. Neurosignals 14 (2005) 126-135
34. Fukushima T., Mitsuhashi S., Tomiya M., Iyo M., Hashimoto K., and Toyo'oka T. Determination of kynurenic acid in human serum and its correlation with the concentration of certain amino-acids. Clin. Chim. Acta 377 (2007) 174-178
35. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., and Dilloo D. Human bone marrow stromal cells inhibit allogenic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004) 4619-4621
36. Massaia M., Dianzani U., Bianchi A., Camponi A., Boccadoro M., and Pileri A. Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clin. Exp. Immunol. 73 (1988) 214-218
37. Pasqualetti P., Collacciani A., and Casale R. Risk of monoclonal gammopathy of undetermined significance: a case-referent study. Am. J. Hematol. 53 (1996) 217-220
38. Lob S., Konigsrainer A., Zieker D., Brucher B.L., Rammensee H.G., Opelz G., et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan metabolism. Cancer Immunol Immunother 58 (2009) 153-157
39. Witkiewicz A., Williams T.K., Cozzitorto J., Durkan B., Showalter S.L., Yeo C.J., et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg 206 (2008) 849-854
40. Denz H., Orth B., Weiss G., Herrmann R., Huber P., Wachter H., et al. Weight loss in patients with hematological neoplasia is associated with immune stimulation. Clin Invest 71 (1993) 37-41
41. Giusti R.M., Maloney E.M., Hanchard B., Morgan O.S., Steinberg S.M., Wachter H., et al. Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraperesis, and adult T-cell leukaemia/lymphoma. Cancer Epidemiol Biomarkers Prev 5 (1996) 699-704
42. Astigiano S., Morandi B., Costa R., Mastracci L., D'Agostino A., Ratto G.B., et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 7 (2005) 390-396
43. Maes M., Mihaylova I., Ruyter M.D., Kubera M., and Bosmans E. The immune effects of TRYCATs (tryptophan catabolites along IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 28 (2007) 826-831
44. Hutchison C.A., Plant T., Drayson M., Cockwell P., Kountouri M., Basnayake K., et al. Serum free light chain measurement aids diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 9 (2008) 11
45. Pawlak D., Tankiewicz A., Myśliwiec P., and Buczko W. Tryptophan metabolism via kynurenine pathway in experimental chronic renal failure. Nephron 90 (2002) 328-335
46. Pawlak D., Tankiewicz A., and Buczko W. Kynurenine and its metabolites in the rat with experimental renal insufficiency. J Physiol Pharmacol 52 (2001) 755-766
47. Vaziri N.D., Goldman R., Schultze R.G., Lee D.B.N., and Rosen S.M. Maintenance hemodialysis in myeloma kidney disease. Western J Med 126 (1977) 91-94